We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The head biosafety expert for China’s Center for Disease Control and Prevention has claimed that the country could have a vaccine ready for general population use as soon as November, touting the country’s rapid progress on COVID-19 vaccine development. Read More
The National Institutes of Health (NIH) is deeply concerned that an unexplained patient illness under review in AstraZeneca (AZ)’s phase 3 COVID-19 vaccine trial could throw the promising candidate off course, and the NIH has opened its own investigation into the issue, an NIH clinical director has disclosed. Read More
Neurocrine Biosciences has finally launched its once-daily Parkinson’s disease add-on treatment Ongentys (opicapone) in the U.S. following months of delay brought on by the COVID-19 pandemic. Read More
China’s state-owned pharmaceutical company, Sinopharm, said that it has already vaccinated hundreds of thousands in the country with its COVID-19 vaccine candidates, even though its phase 3 trials have not yet wrapped up. Read More
Regeneron Pharmaceuticals’ investigational COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial aimed at finding effective treatments. Read More
A late-stage trial of Eli Lilly’s rheumatoid arthritis (RA) treatment Olumiant (baricitinib) and Gilead Sciences’ remdesivir found that the combination reduced recovery time in hospitalized COVID-19 patients compared to remdesivir alone. Read More
The UK government has signed a $1.5 billion agreement with Valneva to supply up to 190 million doses of the French company’s COVID-19 vaccine — enough to provide multiple doses to the UK’s population of almost 68 million. Read More
Roche has unveiled new data for its multiple sclerosis drug Ocrevus (ocrelizumab) that further supports its ability to hinder disease progression. The positive new findings come shortly after the FDA’s recent approval of Novartis’ Kesimpta (ofatumumab), a drug that could prove to be a formidable rival to Roche’s blockbuster product. Read More